Artios Doses First Patient in Phase 1/2a Study of Polθ Inhibitor ART4215

  • Polθ inhibitor, ART4215, is the first selective, orally bioavailable, small molecule inhibitor of the Polθ polymerase domain to enter the clinic
  • Phase 1/2a study evaluating Polθ inhibitor, ART4215, in patients with advanced or metastatic solid tumors
  • Polθ program developed using Artios’s DDR-based platform and small molecule drug discovery capabilities
  • Interim safety and tolerability data expected in 2022
  • Polθ inhibitor, ART4215, is Artios’s second investigational new drug to enter the clinic in 2021 along with ATR inhibitor, ART0380

CAMBRIDGE, UK and NEW YORK, USA, 28 September 2021: Artios Pharma Limited (Artios), a leading biotech company pioneering the development of novel small molecule therapeutics that target the DNA Damage Response process in order to treat patients suffering from a broad range of cancers, announces it has dosed the first patient in its Phase 1/2a study with its polymerase theta (Polθ) inhibitor, ART4215. The Polθ project was originally in-licensed from Cancer Research UK in 2016 as part of the initial formation of Artios.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...